LIFEVANTAGE CORP Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit
LIFEVANTAGE CORP (LFVN) reported Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit of $3.53 per share for the 12-month period ending 2012-06-30, per its 10-K filed 2012-09-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit · last filed 2012-09-10
- LIFEVANTAGE CORP share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2012 was $3.53, a 175.78% increase from fiscal 2011.
- LIFEVANTAGE CORP share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2011 was $1.28.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 12 month |
|---|---|
| 2012-06-30 | $3.53 10-K · filed 2012-09-10 |
| 2011-06-30 | $1.28 10-K · filed 2012-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |